Lebwohl David — SEC Form 4 Insider Trading Activity
Summary
Updated Jul 16, 2026
Lebwohl David is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $110K.
Profile
David Lebwohl is the EVP and Chief Medical Officer of Intellia Therapeutics, Inc. (NTLA), a gene-editing company focused on CRISPR/Cas9-based therapeutics. In the SEC filing dated 2026-01-07 (CIK 0001810882), he is listed as part of the executive leadership, with responsibilities likely centered on medical and clinical strategy for NTLA's programs. Intellia Therapeutics develops CRISPR-based therapies to treat genetically defined diseases.
Role
Insider
Notability
42/100
Board memberships
Intellia Therapeutics, Inc. (NTLA)
Awards & honors
Oversees medical and clinical development at Intellia Therapeutics
Leads strategic direction for CRISPR-based therapeutic programs
David Lebwohl is the EVP and Chief Medical Officer of Intellia Therapeutics, Inc. (NTLA), a gene-editing company focused on CRISPR/Cas9-based therapeutics. In the SEC filing dated 2026-01-07 (CIK 0001810882), he is listed as part of the executive leadership, with responsibilities likely centered on medical and clinical strategy for NTLA's programs. Intellia Therapeutics develop…
Has Lebwohl David been buying or selling stock?
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($110K) across all tracked filings.
Where can I see all of Lebwohl David's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
